Search
Coronavirus-Like Particle COVID-19 Vaccine
go.drugbank.com/drugs/DB15852ExperimentalA Phase 1 clinical trial was launched in July 2020 evaluating the safety, tolerability, and immunogenicity of this vaccine candidate with or without either Cpg 1018 or AS03 (NCT04450004) in adults aged … The Coronavirus-Like Particle COVID-19 Vaccine is in development and testing through Meidcago in Quebec City, Canada.
RUTI® Vaccine
go.drugbank.com/drugs/DB15853InvestigationalMuch like the BCG vaccine, the RUTI® vaccine is also being tested as a prophylactic for SARS-CoV2. … Sponsored by Fundació Institut Germans Trias i Pujol, the RUTI® Vaccine is being tested for prevention of COVID-19 infection in a controlled trial with 315 healthcare worker participants (NCT04453488).
ARCoV
go.drugbank.com/drugs/DB15855ExperimentalManufactured as a liquid, ARCoV is thermostable at room temperature for at least 1 week. … SARS-CoV-2 mRNA vaccine (ARCoV) is a novel mRNA coronavirus vaccine that consists of a lipid nanoparticle-encapsulated mRNA encoding the receptor binding domain of SARS-CoV-2[A220048].
Autologous Non-Hematopoietic Peripheral Blood Stem Cells
go.drugbank.com/drugs/DB15867InvestigationalAutologous non-hematopoietic peripheral blood stem cells have been created into a formulation for use in a clinical trial (NCT04473170) by the Abu Dhabi Stem Cells Center. … The cells have the characterizations of CD90+, CD133+, Oct-4+, CD45-, and CD71-.[L16363]
Methylisothiazolinone
go.drugbank.com/drugs/DB15884InvestigationalSynonyms: 2-Methyl-4-isothiazolin-3-one, 2-Methyl-4-isothiazoline-3-oneCategories: Heterocyclic Compounds, 1-Ring, Compounds used in a research, industrial, or household settingXAV-19
go.drugbank.com/drugs/DB15895InvestigationalAs of July, 2020, the company is conducting a Phase 2 randomized clinical trial to define dosing safety and efficacy of XAV-19 (NCT04453384). … XAV-19 is an intravenous antibody-based treatment targeted towards SARS-CoV-2 and other coronaviruses[L16553,L16558]. The therapy concept is based on [COVID-19 convalescent plasma].
Etesevimab
go.drugbank.com/drugs/DB15897InvestigationalEtesevimab (LY-CoV016, also known as JS016) is a fully human and recombinant monoclonal antibody that targets the SARS-CoV-2 surface spike protein receptor binding domain. … [L16651,L16661] Under the EUA granted in February 2021, etesevimab is used in combination with [bamlanivimab] to treat mild to moderate COVID-19 in adults and pediatric patients who are at high risk for
Atoltivimab
go.drugbank.com/drugs/DB15898ApprovedInvestigationalINMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.[L17320] … [A222078] INMAZEB™, formerly referred to as REGN-EB3, combines the three humanized IgG1κ mAbs Atoltivimab (REGN 3470), [Odesivimab] (REGN 3471), and [Maftivimab] (REGN 3479) in equimolar proportions